C10-Ester Tetracycline Adjuvants Against Destructase Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Tetracycline antibiotic resistance, particularly due to tetracycline destructases (TDases), poses a significant challenge in treating multi-drug resistant pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, Legionella longbeacha, and Mycobacteria abscessus, rendering third-generation tetracycline drugs ineffective.

Innovation Solution

Development of C10-ester derivatives of anhydrotetracycline, including C9-benzamide and C10-benzoate esters, which inhibit tetracycline destructases and can be used in combination with tetracycline antibiotics to overcome resistance mechanisms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If third-generation tetracycline drugs are used to treat multi-drug resistant pathogens, then traditional resistance mechanisms (efflux pumps and ribosome protection proteins) are overcome, but new resistance mechanisms emerge in the form of tetracycline destructases that inactivate all generations of tetracycline antibiotics

Engineering Contradiction:

Improveefficacy of tetracycline antibioticsVSAvoidtetracycline destructase activity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs a dual-component system where a tetracycline antibiotic and a C10-ester derivative work together. The C10-ester derivative acts as an intermediary agent that specifically inhibits tetracycline destructases, preventing them from inactivating the tetracycline antibiotic. This mediator approach allows the tetracycline to maintain its antibacterial activity despite the presence of TDases.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates a composite therapeutic composition combining a tetracycline antibiotic with a C10-ester derivative. This composite approach integrates two distinct molecular entities with complementary functions: the tetracycline provides antibacterial activity while the C10-ester derivative provides TDase inhibition, together overcoming resistance that neither component could address alone.

Inventive Principle:

Principle #40Composite materials

2Productivity

If tetracycline antibiotics are administered alone, then antibacterial activity is exerted, but tetracycline destructases inactivate the antibiotic rendering it ineffective

Engineering Contradiction:

Improveantibacterial activityVSAvoidtetracycline antibiotic stability

Core Design Contradiction:

ProductivityVSStability of the object's composition

Solution Approach 1:

The C10-ester derivative serves as a protective intermediary that binds to and inhibits tetracycline destructases. This prevents the enzymes from degrading the tetracycline antibiotic, thereby stabilizing the antibiotic composition in the presence of resistant bacteria that produce TDases.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The C10-ester derivative provides beforehand cushioning by pre-inhibiting tetracycline destructases before they can inactivate the tetracycline antibiotic. This protective mechanism is in place from the start of treatment, cushioning the antibiotic against enzymatic degradation and ensuring its stability throughout the therapeutic process.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

3Reliability

If new resistance mechanisms are allowed to develop, then bacterial survival is ensured, but the clinical viability of tetracycline drugs of last resort is threatened

Engineering Contradiction:

Improveclinical viability of tetracycline drugsVSAvoidbacterial resistance adaptability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The C10-ester derivative executes preliminary anti-action by specifically targeting and inhibiting tetracycline destructases before they can compromise the clinical viability of tetracycline drugs. This preemptive inhibition counteracts the bacterial adaptability to develop resistance, preserving the effectiveness of these last-resort antibiotics.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The invention converts the harmful effect of tetracycline destructases into a benefit by using the C10-ester derivative to specifically inhibit these enzymes. The bacterial resistance mechanism, which was intended to harm tetracycline efficacy, is instead neutralized and converted into an opportunity for enhanced therapeutic success through the combined composition.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The C10-ester derivatives effectively inhibit TDases, restoring the efficacy of tetracycline antibiotics against resistant bacteria, demonstrating strong antibacterial activity and compatibility with human cells.

Implementation Method 1

The C10-ester derivatives effectively inhibit TDases, restoring the efficacy of tetracycline antibiotics against resistant bacteria

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentUS20260060992A1Compositions for overcoming tetracycline antibiotic resistance and methods of use thereof

Publication Date: 2026.03.05 WASHINGTON UNIV IN SAINT LOUIS

AI summary

Compositions for overcoming tetracycline antibiotic resistance and methods of use thereof are provided. Compositions include at least one compound selected from Formula (I) and Formula (II) as disclosed herein. Methods of treating a subject having a bacterial infection include administering at least one compound selected from Formula (I) and Formula (II) as disclosed herein. In some embodiments, the composition further includes at least one tetracycline antibiotic.